Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)
The most recent articles from:
December 2003
-
Multicenter Study Clinical Trial
[Short course treatment for visceral leishmaniasis with liposomal amphotericin B in immunocompetent patients].
Visceral leishmaniasis is endemic in southern Europe. Traditional treatment consists of pentavalent antimonial compounds. However, treatment failures, the treatment's long duration, and toxicity have led to the introduction of new therapies, such as liposomal amphotericin B (LAB). In this study we evaluate the safety and efficacy of LAB at a maximum dose of 4 mg/kg/day on days 1, 2, 3, 4, 5, and 10. ⋯ A total dosage of 24 mg/kg of liposomal amphotericin B administered in 6 doses within 10 days is safe and effective for the treatment of visceral leishmaniasis and reduces the length of hospital stay.